Skip to main content

Table 1 Registry inclusion / exclusion criteria

From: The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register

Inclusion criteria

Exclusion criteria

• Patients must …

• Patients must not be …

• Have a clinical diagnosis of PsA;

Unable to communicate in English;

• Meet CASPAR classification criteria for PsA [7];

Deemed, in any other way, unable to give informed consent;

• Be aged ≥16 years;

Managed in paediatric rheumatology services;

• Be either:

Currently taking a bDMARD / tsDMARD and not changing treatment;

 (a) Naïve to all bDMARD / tsDMARD agents; or

Restarting a specific bDMARD / tsDMARD agent that they have received previouslya.

 (b) Starting a bDMARD / tsDMARD agent, approved for the treatment of PsA in the United Kingdom, having never previously received that particular druga.

 
  1. aPatients are eligible if they are starting, or switching to, a biosimilar product even if they have previously had (i) the originator product, and/or (ii) a different biosimilar of the same product